Clinical Trials Logo

Clinical Trial Summary

This study is an exploratory single-arm, open, modified "3+3" dose escalation study with BGT007H injection. Approximately 11 to 14 subjects with recurrent/refractory gastrointestinal tumors will be enrolled to evaluate the safety of BGT007H injection. Four dose levels were designed for this study: 1.0×10^8cells, 3.0×10^8cells, 1.0×10^9cells, and 3.0×10^9cells. The primary objective of this study was to evaluate the safety, tolerability and pharmacokinetic profile of BGT007H cell therapy in patients with recurrent/refractory digestive tract tumors, to determine the maximum tolerated dose or the best effective dose, and to initially evaluate the effectiveness of BGT007H cell products.


Clinical Trial Description

Main research objectives: Evaluation of the safety and tolerability of BGT007H cell therapy in patients with recurrent/refractory gastrointestinal tumors Secondary research objectives: 1. Evaluate the pharmacokinetic (PK) characteristics of BGT007H cells after reinfusion; 2. Evaluation of the initial effectiveness of BGT007H cell therapy in patients with recurrent/refractory gastrointestinal tumors Exploratory Purpose 1. Exploring the correlation between the proliferation and survival of BGT007H cells in vivo and their therapeutic effects; 2. Exploring the correlation between target expression levels and efficacy ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06152757
Study type Interventional
Source BioSyngen Pte Ltd
Contact Xinfeng Chen
Phone 0371-66295320
Email fengxinchen1985@163.com
Status Recruiting
Phase Early Phase 1
Start date October 9, 2023
Completion date July 19, 2027

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05922358 - Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors Phase 2
Terminated NCT04171141 - Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. Phase 1
Completed NCT01552291 - The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies Phase 4
Active, not recruiting NCT03833700 - A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) Phase 1
Recruiting NCT06085365 - Effects of Immunonutrition on the Improvement of Postoperative Adjuvant Chemotherapy Related Adverse Reactions in Patients With Gastrointestinal Tumors Phase 3
Completed NCT01640665 - Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors Phase 1
Recruiting NCT04629326 - PD-L1 Targeting Molecular Imaging of Solid Tumors N/A
Recruiting NCT05981235 - Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors Phase 1
Recruiting NCT05262335 - Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001) Phase 2
Terminated NCT01648465 - Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors Phase 2
Not yet recruiting NCT06263205 - Wound Management Following Gl Tumor Surgery: Comparing Outcomes of Dressing Changes Versus Non-Dressing Techniques N/A